Roche has made a shift in its strategy by signing a manufacturing contract with Emcure Pharma for its blockbuster biologics drugs Herceptin and MabThera.
Emcure will manufacture these drugs for Indian market and depending on the success of this drug it will be taken to other developing countries.
Roche is the only company that sells Herceptin and there is no generic substitute for this drug.
These drugs, which are currently under process development, are expected to hit the market by 2013.
Emcure though has not revealed if it is a mere contract manufacturing or a voluntary licence deal.
"This deal will equip Emcure to manufacture products which are sophisticated Monoclonal Antibodies. We look at this project as Emcure's first project with Roche," said Mukund Ranade, director, Emcure Pharmaceuticals.
"Depending on the success of the same, we hope cooperation would become broad based," he said. Biologics drugs are highly complicated molecules and require sophisticated manufacturing capabilities.
Buy the on-demand report Partnering Agreements with Roche
See further details at Current Agreements (subscription required)